Beckman Coulter Life Sciences and Illumina Accelerate Oncology Research with Launch of TruSight Oncology 500 DNA/RNA Application<strong>Indianapolis, IN – (August 6, 2024)</strong> Beckman Coulter Life Sciences offers a promising new approach to oncology research delivering faster results with fewer touchpoints. The Illumina TruSight™ Oncology 500 DNA/RNA assay on the Biomek NGeniuS System from Beckman Coulter Life Sciences provides an innovative automated solution enabling comprehensive genomic profiling of tumor samples.
技术文件
Didn't find what you are looking for? For more results click
此处。
IMPORTANT: Beckman Coulter makes no warranties of any kind whatsoever express or implied, with respect to this App Template, including but not limited to warranties of fitness for a particular purpose or merchantability or that the App Template is non-infringing. All warranties are expressly disclaimed. Your use of the App Template is solely at your own risk, without recourse to Beckman Coulter. This App Template has been demonstrated for use on the Biomek NGeniuS system for the chemistry kit version and the release date shown at the time when the App is selected and created, but has not been validated by Beckman Coulter for use in the diagnosis of disease or other clinical conditions.
Products and demonstrated applications are not intended or validated for use in diagnostic procedures.